Roquefort Thera Regulatory News (ROQ)

24 November 2023

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Change of Auditor

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, announces that RPG Crouch Chapman LLP has been appointed as its new independent auditor with immediate effect.

The Board has approved the appointment of RPG Crouch Chapman LLP as the Company's auditor for the financial year ending 31 December 2023. The re-appointment of RPG Crouch Chapman LLP for the financial year ending 31 December 2024 will be subject to approval by shareholders at the next Annual General Meeting of the Company to be held in 2024.

In accordance with Section 519 of the Companies Act 2006, the Company's previous auditor, BDO LLP, has confirmed that there are no circumstances connected with their resignation which they considered should be brought to the attention of the Company's members or creditors in accordance with Section 519 of the Companies Act 2006.

ENDS

Enquiries:

LEI: ?254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma.

Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.

Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:

· Midkine antibodies with significant in vivo efficacy and toxicology studies;

· Midkine RNA therapeutics with novel anti-cancer gene editing action;

· Midkine mRNA therapeutics with novel anti-cancer approach;

· STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and

· MK cell therapy with direct and NK cell-mediated anti-cancer action

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on X (formerly Twitter).